SUPERNUS PHARMACEUTICALS INC
For the period ended Sep 30, 2024. Filed Nov 4, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 4, 2024
SUPN$28.75+4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| (unaudited) | ||
| Cash flows from operating activities | ||
| Net earnings | $58,537 | $141 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | ||
| Depreciation and amortization | 61,569 | 63,183 |
| Amortization of deferred financing costs and debt discount | — | 532 |
| Amortization of premium/discount on marketable securities | 2,497 | (849) |
| Change in fair value of contingent consideration | (6,466) | (1,313) |
| Realized gains from sales of marketable securities | (9) | — |
| Other noncash adjustments, net | 8,281 | 10,485 |
| Share-based compensation expense | 20,123 | 20,314 |
| Deferred income tax benefit | (20,064) | (15,255) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (1,253) | 21,155 |
| Inventories | 12,619 | 1,082 |
| Prepaid expenses and other assets | (8,542) | (8,138) |
| Accrued product returns and rebates | 14,850 | 10,808 |
| Accounts payable and other liabilities | (14,597) | (36,018) |
| Net cash provided by operating activities | 127,545 | 66,127 |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (542,608) | — |
| Maturities of marketable securities | 365,891 | 335,297 |
| Purchases of property and equipment | (512) | (587) |
| Net cash provided by (used in) investing activities | (177,229) | 334,710 |
| Cash flows from financing activities | ||
| Proceeds from Credit Line | — | 93,000 |
| Payments on Credit Line | — | (93,000) |
| Payment on convertible notes | — | (402,500) |
| Proceeds from issuance of common stock | 8,031 | 5,518 |
| Employee taxes paid related to net share settlement of equity awards | (1,728) | (1,990) |
| Net cash provided by (used in) financing activities | 6,303 | (398,972) |
| Net change in cash and cash equivalents | (43,381) | 1,865 |
| Cash and cash equivalents at beginning of year | 75,054 | 93,120 |
| Cash and cash equivalents at end of period | $31,673 | $94,985 |
| Supplemental cash flow information | ||
| Cash paid for interest on debt | $— | $1,946 |
| Cash paid for income taxes | 40,343 | 27,055 |
| Cash paid for operating leases | 13,224 | 13,242 |
| Noncash investing and financing activities | ||
| Lease assets obtained for new operating leases | $3,547 | $5,903 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.